|Day's Range||34.51 - 34.57|
|52 Week Range||33.39 - 38.86|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.63%|
This specialty has only a handful of ETFs. Find out which one makes sense for you.
The Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) of the FDA, has invited PharmaMar to participate in this ODAC, giving a presentation to provide background information on Zepsyre™, positive clinical data obtained from phases I and II, in which a good tolerance and a good safety profile were observed, and to assess the potential role of this drug in pediatric cancers and hematological disorders. Zepsyre™ (PM1183), PharmaMar´s investigational drug, is one of the three products chosen by ODAC.
When the dust finally settled on Amazon.com, Inc. (NASDAQ: AMZN )’s historic $13.7 billion buyout bid for Whole Foods Market, Inc. (NASDAQ: WFM ) on Friday, Whole Foods stock was up 29.1 percent on the ...